Appili Therapeutics Inc Ordinary Shares APLIF
Trading Information
- Previous Close Price
- $0.01
- Day Range
- $0.01–0.01
- 52-Week Range
- $0.01–0.03
- Bid/Ask
- $0.00 / $4,000.10
- Shares Outstanding
- 132.37M
- Market Cap
- $1.16M
- Volume/Avg
- 12,000 / 26,941
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 4.37
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Appili Therapeutics Inc is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, it develops a pipeline of novel therapies to prevent deaths and improve lives. The company is advancing a diverse range of anti-infectives, including an FDA approved ready-made suspension of metronidazole for the treatment of antimicrobial resistant infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical antiparasitic for the treatment of a disfiguring disease. Its pipeline includes ATI-1701, ATI-1801, ATI-1501.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 7
Valuation
|
Metric
|
APLIF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 4.37 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
APLIF
|
|---|---|
Quick Ratio | 0.06 |
Current Ratio | 0.07 |
Interest Coverage | −2.10 |
Quick Ratio
APLIF
Profitability
|
Metric
|
APLIF
|
|---|---|
Return on Assets (Normalized) | −340.00% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
APLIF
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|DDDs$^ | LOCK|xq&Z | $138B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|!!GprP | LOCK|SyLz | $85B | |||
| argenx SE ADR
ARGX
| LOCK|tjXLS# | LOCK|ts? | $65B | |||
| Moderna Inc
MRNA
| LOCK|>%Cq@dR | LOCK|L% | $58B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|s$&&BDM | LOCK|VKc | $43B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|$>$rS& | LOCK|HH%F$ | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|f@ZfgS@> | LOCK|pg?#@ | $28B | |||
| BioNTech SE ADR
BNTX
| LOCK|K<X$?>T | LOCK|Zb | $26B | |||
| Incyte Corp
INCY
| LOCK|&<>C$s | LOCK|lT | $26B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|&^nHBW> | LOCK|Ql | $16B |
United States